

ONE HUNDRED SIXTEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115

Majority (202) 225-2927  
Minority (202) 225-3641

January 13, 2020

Mr. Saeed Motahari  
President and CEO  
Insys Therapeutics, Inc.  
1333 S. Spectrum Boulevard, Suite 100  
Chandler, AZ 85286

Dear Mr. Motahari:

We are continuing our work investigating the causes and effects of the opioid epidemic. Last Congress, the Committee on Energy and Commerce began bipartisan investigations into fentanyl, opioid manufacturing, opioid distribution, and the substance use disorder treatment industry. We write today to reactivate the investigation started on August 2, 2018, that examined potential breakdowns in the controlled substances supply chain, which may have contributed to the nation's opioid epidemic, and the role of certain opioid manufacturers in such potential breakdowns.

Last year, we sent a letter to Insys Therapeutics requesting information and documents (see attached). In response to this letter, Insys Therapeutics produced information and documents that were partially responsive to the letter. We note that of the 16 request items from the August 2, 2018 letter, Insys Therapeutics only produced responses to request items 2b, 2c, 3, and 4. We now seek to ensure a full response to that request letter. Please produce responses to the remaining request items to the attached August 2, 2018 request letter by February 13, 2020.

If you have any questions, please contact Jen Barblan or Alan Slobodin of the Minority Staff at (202) 225-3641. Thank you for your prompt attention to this matter.

Sincerely,



---

Greg Walden  
Republican Leader



---

Brett Guthrie  
Republican Leader  
Subcommittee on Oversight  
and Investigations



---

H. Morgan Griffith  
Member of Congress

Attachment